External Quality Assurance (EQA) Program for

Neonatal G6PD Screening Test

Notes
	2024 External Quality Assurance (EQA) Program for Neonatal G6PD Screening Test [EQA Survey Schedule for 2024]
	Annual Summary of External Quality Assurance Survey for Neonatal G6PD Screening Test (2023)
	Application Forms	Accredited to ISO/IEC 17043

G6PD EQA MIS System [login]

FAQ : [website security certificate Problem]

Introduction：

　　Glucose-6-phosphate dehydrogenase (G6PD; EC1.1.1.49) deficiency is the most common enzymopathic disease in Southeast Asia and other tropical areas worldwide. This X-linked genetic disorder (MIM 305900) has been found to be an important cause of neonatal jaundice and acute haemolytic anemia in the southern Chinese population in Taiwan.  In order to reduce the complications of G6PD deficiency, such as kernicterus, permanent neurological damage and death, nationwide neonatal screening for G6PD deficiency was started on 1 July 1987 after a pilot project conducted between November 1984 and June 1987 had demonstrated the practicality and the efficiency of neonatal screening of G6PD deficiency in Taiwan.  The effective collection rate has reached more than 99% of all newborns in Taiwan since 1996 and the overall incidence rate of G6PD deficiency was found to be about 2%.  To assess the reliability and to improve the quality of the screening tests performed by each neonatal screening center, an external quality assurance (EQA) program for determination for blood G6PD activity was developed since 1999.

        Periodically, 10 QC specimens were randomly picked for each survey and distributed to each neonatal screening laboratory by speed post delivery.  Reports were requested to be returned by facsimile (and internet submission since 2005) within 3 days for screening centers in Taiwan and 9 days for overseas screening centers.  For each QA survey, the G6PD activity of the QC dried blood spots was determined by quantitative assay to set the reference values before the QC specimens were send out.  The results reported by the screening centers were evaluated against the consensus result and compared with the quantitative reference values determined by our laboratory.  The summary report for each survey was published on website within two weeks after the survey started.  

Participating Laboratories

Summary Report of EQA Survey for Neonatal G6PD Screening Test :

January 2024~

　　　　  1. Survey No : NS2024-01

　　　　  2. Survey No : NS2024-02

　　　　  3. Survey No : NS2024-03

 

July 1998~December 2023

Annual Summary

Publication Related to this G6PD EQA Program

Announcement Related to this G6PD EQA Program